Dorsey Wright & Associates Krystal Biotech, Inc. Transaction History

Dorsey Wright & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 23, 2020	SELL	$37.03 - $60.0 $14,441 - $23,400	-390 Closed	0 $0
Q1 2020 Apr 20, 2020	SELL	$35.02 - $65.64 $2,346 - $4,397	-67 Reduced 14.66%	390 $17,000
Q2 2019 Jul 02, 2019	BUY	$27.2 - $41.2 $3,100 - $4,696	114 Added 33.24%	457 $18,000
Q1 2019 Apr 04, 2019	SELL	$19.86 - $32.9 $6,792 - $11,251	-342 Reduced 49.93%	343 $11,000
Q4 2018 Jan 07, 2019	BUY	$15.03 - $25.38 $10,295 - $17,385	685 New	685 $14,000

310

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.23B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

Stay updated on Dorsey Wright & Associates with notifications on news.